ATG16L1 and epilepsy: A study reported that increasing ATG16L1 levels through antagomir-223 treatment alleviated epilepsy in KA-treated mice, suggesting the microRNA-223/ATG16L1 pathway may offer a novel treatment option for TLE [23].